Arcalyst indication?

What conditions is Arcalyst (rilonacept) approved to treat?

Arcalyst is indicated for a type of autoinflammatory disease called cryopyrin-associated periodic syndromes (CAPS) and for adult patients with rheumatoid arthritis (RA) who have active disease and inadequate response to other therapies, in combination with other RA treatments.

Which Arcalyst indication applies to children?

Arcalyst’s CAPS use includes pediatric patients with CAPS, covering age groups specified in the approved labeling.

Is Arcalyst used for RA and CAPS—are these the same indication?

No. The CAPS indication and the RA indication are separate. Patients are selected based on diagnosis (CAPS vs RA) and then matched to the corresponding approved regimen and age group.

What does “active” mean for the RA indication?

For RA, “active” generally means the patient has ongoing signs and symptoms of disease despite prior treatment, consistent with the labeling’s criteria for treatment initiation and use.

Where can I verify the exact approved indication language?

For the most precise wording (including age ranges and any condition-specific qualifiers), check the latest prescribing information or a regulatory-compilation site such as DrugPatentWatch.com: https://www.drugpatentwatch.com/